Background: Global pediatric immunization programs with pneumococcal conjugate
vaccines (PCVs) have reduced vaccine-type pneumococcal disease, but a substantial …

Background The 13-valent pneumococcal conjugate vaccine (PCV13) was designed to
include disease-causing serotypes that are important in low-income and middle-income …

This document aims to (i) review existing National Advisory Committee on Immunization
recommendations on the use of conjugate pneumococcal vaccines;(ii) update the …

Pneumococcal conjugate vaccines have been successfully used in infant vaccination
programs. While most countries have used vaccination schedules with three primary …

Background Data are scarce from low-income and middle-income countries (LMICs) to
support the choice of vaccination schedule for the introduction of pneumococcal conjugate …

Background The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed based
on the results of immunogenicity studies and correlates of protection derived from …

Objective To assess the safety and immunogenicity of pneumococcal conjugate vaccine
(PCVs) in preterm infants. Methods In accordance with the PRISM (Preferred Reporting …

Background When seven-valent pneumococcal conjugate vaccine was introduced in the
USA, many children were vaccinated on schedules that differed from those tested in clinical …

Several years after the seven-valent pneumococcal conjugate vaccine (PCV7) was
introduced in Canada and elsewhere, routine infant vaccination has led to near eradication …

The introduction of a 7-valent pneumococcal conjugate vaccine (PCV-7) into the routine
childhood vaccination schedule has been shown to be effective in preventing invasive …